Tisseel-Lyo

Quick links

Choose a section

Quick links to important sections

Advertisements

Tisseel-Lyo

Advertisements
Advertisements

Method of action: Antihemorrhagics, Fibrin Sealant

Treatment option:

Advertisements

Overview of Tisseel-Lyo

Tisseel-Lyo: Quick Facts and Foundational Identity

Tisseel-Lyo is a specialized biological product defined by its core active components, Human Fibrinogen and Human Thrombin, supplied as a Lyophilized Powder within a kit for topical application. It is classified as a Topical Hemostatic Agent, also known as a Fibrin Sealant, and its primary function is to assist in Hemostasis and Biological Sealing.

What is Tisseel-Lyo and What Type of Agent is it?

Tisseel-Lyo is classified as a combination biological product and a Topical Hemostatic Agent, fundamentally used to support bleeding control and tissue closure in surgical procedures. It belongs to the class of Fibrin Sealants, acting as a rapid tissue adhesive. This medicine is designed to rapidly achieve a stable clot in situations where conventional methods may be inadequate. The product is derived from Human Plasma donations, a key attribute that dictates its components, Fibrinogen and Thrombin, are purified, naturally occurring proteins. The specific inclusion of the stabilizer Aprotinin and the delivery method distinguishes the Tisseel formulation as a widely recognized option within its class for its reliability in establishing clot integrity.

Composition and the Role of Lyophilized Components

The unique presentation of Tisseel-Lyo is supplied as a Kit for Solution for Sealant, distinguished by the components being in a Lyophilized Powder state before reconstitution for topical use. This specialized, freeze-dried form is essential for preserving the maximum stability and biological activity of the protein components, Human Fibrinogen and Human Thrombin, until the point of preparation. The kit also integrates crucial excipients, including Calcium Chloride (CaCl2), which is required to fully activate the Thrombin enzyme, and Aprotinin, a synthetic inhibitor that increases the stability and longevity of the newly formed Fibrin clot, which supports clot resistance to premature enzymatic breakdown.

General Purpose: Hemostasis and Biological Sealing

The general purpose of this product is to rapidly establish localized clotting and provide immediate mechanical support for Biological Sealing. By directly supplying and combining Fibrinogen and Thrombin, the product effectively and predictably bypasses the preceding steps of the natural Coagulation Cascade. This localized enzymatic action rapidly converts the Fibrinogen into a stable, adhesive Fibrin matrix that aids in achieving effective Hemostasis and supports the approximation of tissue surfaces in a typical use scenario like reinforcing an anastomosis or sealing large tissue surfaces after surgical dissection.

Advertisements

What side effects are possible with Tisseel-Lyo ?

Possible Side Effects and Safety Information

Tisseel-Lyo is a fibrin sealant derived from pooled human plasma and contains synthetic aprotinin, components that underpin its safety profile and key risks.

Serious and Clinically Significant Risks

Official regulatory information highlights several serious risks:

  • Thromboembolic Events: The product must not be injected into a blood vessel (intravascularly) as this can lead to severe and life-threatening blood clots, including cerebral artery embolism.
  • Hypersensitivity and Anaphylaxis: Allergic reactions, including life-threatening anaphylactic shock, have been reported. The risk is elevated in patients with a history of hypersensitivity to any of the product's components, particularly aprotinin, or those who have received aprotinin previously.
  • Air or Gas Embolism: Life-threatening or fatal air or gas embolism may occur when the sealant is applied using a spray device with pressurized gas. This risk is specifically related to inappropriate technique, such as using higher than recommended pressures or spraying too close to the tissue surface. Monitoring of patient vital signs is recommended during spray application.

Other Documented Adverse Reactions

Adverse reactions have been categorized by frequency, although the frequency of many post-marketing events remains not known.

System Organ Class Common (Reported in Clinical Trials) Uncommon/Not Known (Post-Marketing)
Infections Postoperative wound infection Increased fibrin degradation products
Immune System – Hypersensitivity reactions, Anaphylactic reaction
Vascular – Hypotension, Hematoma, Arterial and Air Embolism
General – Chest discomfort, Pain in extremity, Pyrexia

Safety Restrictions and Contexts of Use

Tisseel-Lyo is contraindicated in individuals with known hypersensitivity to any of the active substances or excipients. Its use is also not indicated for the treatment of severe or brisk arterial or venous bleeding, as the sealant will be washed away before clotting can occur. The safety and effectiveness of the sealant have not been evaluated for use in neurosurgical procedures or other surgeries involving confined spaces. Due to its human plasma origin, the product carries a theoretical risk of transmitting infectious agents, such as viruses.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for this fibrin sealant is defined by the absence of systemic overdose symptoms typically associated with orally or intravenously absorbed medications. The official concern is centered on the consequences of administration error and misuse.

Domain Official Regulatory Statement
Documented overdose presentations Systemic overdose symptoms are generally not documented due to the product’s intended topical application route. The primary presentations are severe outcomes resulting from administration error.
Physiological systems affected Coagulation/Vascular System: Associated with risks of Disseminated Intravascular Coagulation (DIC) and thromboembolic events following prohibited intravascular administration.
Emergency-response statements The application must be immediately discontinued upon suspicion of intravascular administration or severe acute reaction.
When immediate medical help is required Seek immediate medical attention upon suspicion of accidental intravascular administration or severe complication.

Official overdose statements:

  • The most severe documented outcomes are linked to the prohibited intravascular administration, leading to the risk of Disseminated Intravascular Coagulation (DIC) and acute thromboembolic events.
  • Regulatory sources confirm that no specific antidote is known for Tisseel-Lyo.
  • Management of complications is restricted to providing appropriate symptomatic and supportive treatment.

Connection to the overall overdose profile:

Government regulatory documents define the overdose risk not by dose, but by the potential for life-threatening vascular complications that result from the strictly forbidden intravascular administration. The official guidance mandates that individuals seek immediate medical attention and requires product discontinuation if this administration error is suspected, as treatment is limited to supportive measures due to the absence of a specific antidote.

Advertisements

Therapeutic Uses of Tisseel-Lyo

What Tisseel-Lyo Treats: Main Uses and Benefits

Tisseel-Lyo is generally used as a supportive medical application in the operating room, addressing issues where a biological seal or supportive blood control is needed beyond the capacity of traditional surgical techniques. Its therapeutic scope is defined by two key functional domains that may contribute to overall comfort during the period of surgical recovery.

This agent is commonly used in conditions presenting with acute episodes that require support for controlling localized bleeding during surgery, addressing the risk of post-operative leakage of fluids, and reinforcing surgical closures or securing implanted materials.

Enhanced Support in Surgical Scenarios

This application plays a role in managing symptoms related to excessive blood loss when conventional methods are deemed impractical or insufficient. It helps manage symptom clusters that may become intense or disruptive, especially in patients who are systemically anticoagulated (e.g., heparinized), which helps support the patient during this difficult episode.

“This agent is relevant when supportive symptom management is appropriate to support the management of a stable surgical site.”

The use of this sealant is also relevant in contexts marked by increased discomfort related to tissue instability, where it assists with maintaining functional stability by securing materials like surgical meshes or grafts.

Quick Fact: Focus on Localized Hemorrhage Support Tisseel-Lyo is applied when symptoms create noticeable physiological strain, is used for managing bleeding patterns that challenge standard surgical methods, which may assist with easing the physiological strain.

Advertisements

Eligibility and Restrictions for Use

Tisseel-Lyo is formally designated for use as an adjunct to hemostasis and sealing in adult and pediatric patients older than one month of age undergoing surgery. The official eligibility profile is strictly defined by regulatory contraindications and age-based limitations.

Populations Who Must Not Use the Medicine (Contraindications)

Use is prohibited for individuals with a known hypersensitivity to the component aprotinin or any other ingredient. The product is also contraindicated for the treatment of severe or brisk arterial or venous bleeding. Crucially, the medicine is for topical use only and must never be injected directly into the circulatory system (intravascularly).

Restricted and Conditional Use

The safety and effectiveness of the medicine have not been established for infants one month of age and younger (le 1 month). Caution is recommended for use in both pregnant and lactating women, and administration during pregnancy is permitted only if clearly needed. The regulatory profile also notes that the safety of the product has not been evaluated for use in certain contexts, such as neurosurgical procedures. Additionally, patients with a history of prior aprotinin exposure require caution due to an increased risk of hypersensitivity reactions.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tisseel-Lyo has a specialized interaction profile that reflects its topical application as a biological sealant, focusing primarily on localized incompatibilities and functional interference rather than systemic drug-drug interactions.

Systemic Drug-Drug Interactions

Formal regulatory documentation confirms that no formal interaction studies have been performed to evaluate pharmacokinetic or systemic interactions between Tisseel-Lyo and other co-administered medicinal products. The product label states there are no known systemic interactions with other medicinal products.

Functional and Chemical Incompatibilities

Specific restrictions are defined regarding co-administration and preparation:

  • Oxidized cellulose-containing preparations can reduce the efficacy of the sealant and must not be used as carrier materials at the application site.
  • The product must not be mixed with any other medicinal product during preparation or application.
  • The sealant is susceptible to denaturation when exposed to certain solutions. Agents such as alcohol, iodine, and heavy metals cause a chemical breakdown of the product’s active components, and these substances must be removed from the application site before Tisseel-Lyo is applied.

Use with Anticoagulants

Official prescribing information notes that the product's localized clotting function has been clinically demonstrated even in patients who are fully heparinised, indicating that systemic Heparin does not negate the sealant's function at the application site.

Advertisements

Mechanism of Action

Tisseel-Lyo functions as a topical fibrin sealant, directly engaging the final common pathway of the coagulation cascade at the application site. The two primary biological targets, human fibrinogen and human thrombin, are applied simultaneously.

The thrombin component acts as an enzyme agonist, catalyzing the proteolytic cleavage of fibrinogen into fibrin monomers. These fibrin monomers spontaneously self-assemble to form a soluble fibrin clot. Concurrently, Factor XIII (present in the fibrinogen component) is activated by thrombin in the presence of calcium ions, generating Factor XIIIa.

Factor XIIIa functions as a transglutaminase enzyme, creating covalent cross-links between adjacent fibrin monomers. This cross-linking process converts the soluble fibrin clot into a mechanically stable, insoluble fibrin polymer matrix. The matrix adheres to the tissue surface, forming a localized mechanical barrier. Additionally, aprotinin, a serine protease inhibitor, is present to inhibit the proteolytic activity of plasmin, a key enzyme in the fibrinolytic pathway. This anti-fibrinolytic action maintains the structural integrity of the localized fibrin polymer matrix, modulating its degradation rate.

Advertisements

Dosage and Administration Information

How to Use Tisseel-Lyo

Tisseel-Lyo is a biological product used exclusively as a topical sealant within a controlled surgical setting, involving specific preparation, administration, and volume-based dosing. It is strictly forbidden to inject this product into blood vessels.


Dosing and Administration Principles

Usage Domain General Principles
Route of Administration For topical, localized application only. Systemic administration is prohibited.
Dosing Volume The dose is variable, determined by the size of the area requiring sealing. Typical single application volumes range from 0.5 mL to 4.0 mL.
Frequency Used as a single, one-time application during one surgical procedure.
Population Adjustment No dose adjustments are mandated for older adults or patients with renal or hepatic impairment.

Procedural Use Requirements

Proper use requires specific steps to prepare the product immediately prior to its administration. The lyophilized components must first be reconstituted and warmed to a temperature between 33°C and 37°C to ensure the biological activity of the proteins. The sealant is then applied via a specialized double-syringe system which ensures the two components mix only upon delivery to the surgical site.

Administration must occur on a clean, dry surgical field to facilitate proper matrix formation and adherence. The usage is restricted to the operating room and must be performed by qualified medical specialists. These instructions collectively establish the product as a procedural, context-dependent surgical application with a highly localized, short-term function.

Advertisements

Recent Clinical Evidence

Tisseel-Lyo: Recent Clinical Evidence

Clinical research has focused on the use of Tisseel-Lyo (a fibrin sealant) as an adjunct to standard surgical methods for achieving hemostasis (stopping bleeding) and tissue sealing.

Studies generally evaluate the product’s performance in situations where traditional surgical techniques, such as sutures or cautery, are impractical or have been unsuccessful. This research has covered a variety of surgical specialties, including cardiac, vascular, and general surgery.


Key Areas of Study

Research Focus Primary Outcome Evaluated
Adjunctive Hemostasis The proportion of patients who achieve hemostasis within a specified time frame (e.g., 4 minutes) at the application site.
Tissue Sealing Prevention of leakage from surgical sites, such as colonic anastomoses following reversal of temporary colostomies.
Specific Patient Groups The product's application and effect in heparinized patients (those receiving anticoagulant therapy).

Safety and Tolerability Observations

Clinical trials monitor the occurrence of adverse events in patients receiving Tisseel-Lyo during surgery. The safety profile observed across various studies typically reflects the risks expected in surgical patient populations. Data collection includes tracking the incidence of hypersensitivity reactions, which are a known risk associated with products containing synthetic aprotinin.

Research continues to explore the product's effectiveness and safety in complex surgical procedures and in specific patient populations, with ongoing surveillance for potential serious adverse events.

Key Studies & References

  1. HIGHLIGHTS OF PRESCRIBING INFORMATION (TISSEEL Fibrin Sealant) - FDA Approved Labeling
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tisseel-Lyo (FAQ)

Q: Is Tisseel-Lyo the same as Tisseel?

A: The product is a Fibrin Sealant sharing the same core proteins, Human Fibrinogen and Human Thrombin, as Tisseel. The specific designation Lyo is a reference to its lyophilized (freeze-dried) powder form. This form requires reconstitution before use and is one of the presentations available for the sealant.

Q: How long does the effect of Tisseel-Lyo last in the body?

A: According to the official product information, the product is designed to be resorbed (broken down and absorbed) by the body's natural processes, similar to a physiological blood clot. Official information describes the resorption process as typically taking place over a period of 7 to 14 days.

Q: Do they need to remove Tisseel-Lyo after it seals the tissue?

A: No, the product does not require removal after it is applied. It forms a stable fibrin matrix that adheres to the tissue surface. This matrix is designed to be naturally absorbed by the body over time through its normal enzymatic processes.

Q: Are there any known interactions between Tisseel-Lyo and herbal supplements?

A: Formal interaction studies with herbal supplements or most other medicines have not been performed, and no systemic interactions are known. However, the regulatory label warns that the product can be chemically denatured (broken down) if it comes into contact with agents such as alcohol, iodine, or heavy metal ions. Regulatory information instructs that these substances must be removed from the application site before the sealant is used.

Q: What should a patient tell their doctor before treatment with Tisseel-Lyo?

A: Official safety information indicates that patients should disclose any known allergies, especially if they have had a prior reaction to the component aprotinin or any other ingredient in the sealant. Because the product is derived from human plasma, the official label describes the need for the physician to discuss the low, theoretical risk of transmitting infectious agents.

Q: What does 'Lyo' mean in Tisseel-Lyo?

A: The 'Lyo' in the name is an abbreviation for lyophilized, which is the technical term for freeze-dried. This specialized preparation method is used to preserve the maximum stability and biological activity of the Human Fibrinogen and Human Thrombin proteins. The product is then reconstituted with liquid before it is applied.

Q: Is Tisseel-Lyo used in dental or oral surgery?

A: Regulatory indications state the product is used for hemostasis (stopping bleeding) and tissue sealing across a wide variety of surgical procedures. While the product is a fibrin sealant often discussed in oral or maxillofacial contexts, the official prescribing information does not specifically list these specialties as an indication.

Q: Does Tisseel-Lyo help with wound healing?

A: Tisseel-Lyo is specifically indicated as an adjunct (a supplement) to assist with hemostasis and sealing. Official documents caution that the application of an excessively thick fibrin clot can potentially interfere negatively with the underlying process of wound healing. Therefore, its primary function is localized sealing, not to promote overall tissue repair.

Q: Is Tisseel-Lyo a prescription-only product?

A: The product is classified as a biologic product that is administered only by qualified medical specialists. Because its use is restricted to the operating room and it is not available for patient self-administration, its administration is restricted to the hospital setting under the direction of a physician.

Q: Are there any long-term follow-up studies available for Tisseel-Lyo?

A: Official safety and efficacy data is collected in clinical trials. Long-term studies on fibrin sealants are routinely conducted to assess outcomes over time. These studies track critical outcomes like the recurrence of leakage or the occurrence of adverse events over observation periods of up to six months following the surgical application.

Q: Can Tisseel-Lyo be used in minimally invasive procedures?

A: Yes, official documents mention that specialized application devices are available for use in these contexts. For example, specific spray applicators are recommended for use in minimally invasive surgery (MIS) procedures performed in enclosed body areas.

Q: Does Tisseel-Lyo have any effect on nerve function?

A: The safety and effectiveness of the sealant have not been evaluated for use in neurosurgical procedures or other surgeries involving confined spaces. Official information provides this caution due to the potential for risks to surrounding sensitive structures, which would include nerves.

Q: Is Tisseel-Lyo a standard part of care for certain types of surgery?

A: The product is formally indicated for use as an adjunct (a supplemental aid) to standard surgical techniques. It is typically used by surgeons when conventional methods for controlling bleeding, such as sutures or cautery, are found to be ineffective or impractical during the procedure.

Advertisements

How should Tisseel-Lyo be stored and disposed of?

How to Store and Dispose of Tisseel-Lyo

Storage of the TISSEEL-Lyo kit is defined by strict regulatory requirements to maintain product stability. The unopened freeze-dried kit must be stored between 2 C and 25 C (36 F and 77 F).

Storage Condition
Temperature Range (Unopened) 2 C to 25 C
Prohibited Storage Do not freeze the kit or the reconstituted solutions.
Protection Store in the outer carton to protect from light.
Child Safety Keep out of the reach and sight of children.

After reconstitution, the prepared solution must be used within a maximum of four hours. The solution must not be refrigerated or refrozen after mixing. The product is intended for single-patient use only. Any unused product, including remaining components or solutions that exceed the four-hour limit, must be discarded according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tisseel-Lyo  found in:

A-Z Index: